CCG-203920 did not affect the improvement of rotarod performance ON L-Dopa induced by AT-403
To investigate whether CCG-203920 increased the sedative effects along with the antidyskinetic effect of AT-403, the rotarod performance was monitored before (baseline, OFF L-Dopa) and after L-Dopa administration in dyskinetic rats (Arcuri et al. , 2018; Marti et al. , 2012; Paolone et al. , 2015) (Fig. 5B). As expected, the time spent on the rod after L-Dopa administration was dramatically reduced compared to baseline due to dyskinetic movement appearance (-76%; df=10 t=4.075). When animals were pretreated with AT-403, the rotarod performance ON L-Dopa improved and no significant reduction with respect to baseline condition was observed (Fig. 5B). CCG-203920 administration did not worsen the motor promoting effect of AT-403, indicating RGS4 blockade did not potentiate AT-403-induced sedation.